What is Viz.ai?
Viz.ai is at the forefront of applying artificial intelligence within the healthcare sector. The company's mission is to fundamentally improve global healthcare delivery by developing intelligent software. These advanced solutions aim to expedite treatment timelines and broaden access to critical medical care. Operating from hubs in San Francisco and Tel Aviv, Viz.ai leverages cutting-edge AI to address significant challenges in healthcare efficiency and patient outcomes, positioning itself as a key innovator in the health-tech landscape.
How much funding has Viz.ai raised?
Viz.ai has raised a total of $282.5M across 6 funding rounds:
Series A
$21M
Series B
$50M
Series C
$71M
Series D
$100M
Private Equity
$40M
Grant
$510K
Series A (2018): $21M with participation from GV and Kleiner Perkins
Series B (2019): $50M led by GV, CRV, Greenoaks, Threshold Ventures, and Kleiner Perkins
Series C (2021): $71M supported by Scale Venture Partners and Insight Partners
Series D (2022): $100M featuring Tiger Global Management and Insight Partners
Private Equity (2023): $40M backed by CIBC Innovation Banking
Grant (2023): $510K with participation from U.S. Food & Drug Administration
Key Investors in Viz.ai
Tiger Global Management
Tiger Global Management is an investment firm that deploys capital across both public and private markets, known for its significant investments in technology and growth-stage companies.
Insight Partners
Insight Partners is a global venture capital and private equity firm focused on investing in high-growth technology and software companies, providing operational support to help them scale.
GV
GV is a venture capital firm that invests across multiple stages and sectors, with a focus on enterprise solutions, life sciences, and frontier technology innovations.
What's next for Viz.ai?
The substantial enterprise-level funding Viz.ai has garnered, including its recent strategic investment, signals a robust growth phase, likely moving beyond early-stage development into a scaling or expansion phase. This capital infusion is expected to fuel further innovation in their AI-driven healthcare solutions, potentially expanding their market reach, enhancing product development, and forging new strategic partnerships. The company's trajectory suggests a continued focus on solidifying its leadership in AI for healthcare, with an eye toward broader adoption and impact on global health systems.
See full Viz.ai company page
